Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.91B 11.29B 10.42B 9.64B 18.29B 1,232B 18.6B 125B 48.9B 605B 48.47B 47.42B 2,096B P/E 2026 *
-80.3x
P/E 2027 * 56.7x
Enterprise Value 12.38B 10.83B 9.99B 9.24B 17.54B 1,182B 17.84B 120B 46.89B 580B 46.48B 45.48B 2,010B EV / Sales 2026 *
8.28x
EV / Sales 2027 * 5.36x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.95%
1 week+6.04%
Current month+4.29%
1 month+17.43%
3 months+6.81%
6 months+8.94%
Current year-3.83%
1 week 522.06
Extreme 522.06
569.44
1 month 460.89
Extreme 460.89
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Director/Board Member 74 30/06/2016
Director/Board Member 68 10/08/2016
Director/Board Member 64 26/06/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Founder

1,220 0.0053%
06-16Free

Director

1,220 0.0053%
06-16
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%+6.04%+81.47%+155.56% 12.91B
-0.85%-4.86%+62.83%+124.80% 56.98B
+4.91%-0.19%+73.70%+92.14% 53.58B
+1.48%+5.97%+22.59%+495.47% 25.63B
-0.59%-4.68%-16.82%-12.99% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-1.59%+1.82%+36.43%-25.54% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+3.51%+53.81% - 14.13B
+1.76%+2.24%+29.57%+195.70% 14.35B
Average +0.86%+1.38%+59.43%+152.57% 25.51B
Weighted average by Cap. +1.11%+0.01%+58.32%+143.27%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.12B 2.12B 143B 2.15B 14.45B 5.66B 70.1B 5.61B 5.49B 243B 2.21B 1.93B 1.78B 1.65B 3.13B 211B 3.18B 21.31B 8.35B 103B 8.28B 8.1B 358B
Net income -201M -176M -162M -150M -285M -19.19B -290M -1.94B -761M -9.42B -755M -738M -32.64B 308M 269M 248M 230M 436M 29.37B 443M 2.97B 1.17B 14.42B 1.16B 1.13B 49.96B
Net Debt -529M -463M -427M -395M -750M -50.51B -762M -5.11B -2B -24.81B -1.99B -1.94B -85.92B -1.09B -958M -883M -817M -1.55B -104B -1.58B -10.58B -4.15B -51.31B -4.11B -4.02B -178B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
09/07/26 US$560.01 -0.95% 379,035
08/07/26 US$565.40 +3.67% 468,252
07/07/26 US$545.36 +3.00% 318,420
06/07/26 US$529.48 +0.26% 230,982
02/07/26 US$528.10 +2.67% 221,894
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
560.01USD
Average target price
678.71USD
Spread / Average Target
+21.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock